BOSTON, July 27, 2026. Bambusa Therapeutics reported preliminary proof-of-concept data for BBT001, a long-acting bispecific antibody designed to block two pathways involved in atopic dermatitis, with clinical responses appearing within the first week of treatment and itch relief reported as early as the first day.

The findings come from 17 biologic-naive patients with moderate-to-severe atopic dermatitis enrolled in a global Phase 1 trial. Twelve received BBT001 and five received placebo. The trial is evaluating intravenous and subcutaneous formulations in healthy volunteers and patients, with safety and tolerability as its primary endpoints.

BBT001 targets interleukin-4 receptor alpha and interleukin-31. The first target is central to type 2 inflammation and is already clinically validated in atopic dermatitis. Interleukin-31 is strongly associated with pruritus, making the combination an attempt to address both inflammatory disease activity and the itch that drives much of the condition’s daily burden.

Patients in the proof-of-concept cohort were randomised two to one to receive 450 mg of intravenous BBT001 or placebo every two weeks for four weeks at sites in New Zealand and the United States.

As of the June 8 cutoff, all 17 participants were evaluable, with median follow-up of 71 days. Bambusa said BBT001 produced a statistically significant placebo-adjusted improvement in the Eczema Area and Severity Index beginning at Week 1. The improvement deepened through Week 12 among patients with available follow-up.

The company also reported itch reduction beginning on Day 1 after the first dose, alongside suppression of type 2 inflammatory biomarkers. Bambusa characterised the pharmacokinetic profile as supportive of infrequent maintenance dosing, citing an extended half-life. It also reported low immunogenicity and a favourable preliminary safety profile.

The dataset remains small and exploratory. With only 12 treated patients and five placebo recipients, the study cannot establish the magnitude or durability of benefit expected in a broader population. Baseline differences can also have an outsized effect in cohorts of this size. The trial was designed primarily to assess safety, not to provide a definitive efficacy comparison.

Still, the timing of the responses will attract attention in a competitive atopic dermatitis market. Patients and clinicians increasingly expect therapies to improve both visible disease and itch quickly. A bispecific that combines established inflammatory biology with direct targeting of an itch-associated pathway could offer a differentiated profile if the signal holds in larger trials.

Bambusa expects additional topline results from ongoing BBT001 studies in atopic dermatitis and chronic spontaneous urticaria in the first half of 2027. Those data will need to confirm the preliminary efficacy signal, clarify dose and route, and show whether the proposed extended dosing interval can be achieved without losing disease control.

For now, BBT001 has crossed an important early threshold. The program has produced a human signal consistent with its dual-target rationale. The next study must show that the signal is reproducible at a scale that supports meaningful comparisons with an increasingly strong standard of care.